+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Kidney Disease (CKD) - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 200 Pages
  • May 2022
  • Region: Global
  • DelveInsight
  • ID: 4745374
This “Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic-kidney-disease-chronic-renal-failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Chronic-kidney-disease-chronic-renal-failure: Understanding


Chronic-kidney-disease-chronic-renal-failure: Overview


Chronic Kidney Disease is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease. People with chronic kidney disease may not feel ill or notice any symptoms. CKD signs and symptoms develop over time if kidney damage progresses slowly. Loss of kidney function can cause a buildup of fluid or body waste or electrolyte problems. The most common symptoms of chronic kidney disease include: hypertension, anemia, edema, fatigue, decreased urine output, blood in urine, dark urine, loss of appetite and persistent itchy skin. Patients feel unwell or have symptoms with mild-to-moderate chronic kidney disease that is, stages 1 to 3. Chronic kidney disease is usually diagnosed by the eGFR test before any symptoms develop. Symptoms tend to develop when chronic kidney disease becomes severe (stage 4) or worse. The symptoms at first tend to be vague and nonspecific, such as feeling tired, having less energy than usual and just not feeling well. The most common cause of chronic kidney disease is diabetes and high blood pressure. Each kidney contains about 1 million tiny filtering units, called nephrons. Any disease that injures or scars the nephrons can cause kidney disease. Diabetes and high blood pressure can both damage the nephrons. High blood pressure can also damage the blood vessels of your kidneys, heart, and brain. The kidneys are highly vascularized, meaning they contain lots of blood vessels. So, blood vessel diseases are generally dangerous to your kidneys. If uncontrolled, or poorly controlled, high blood pressure can be a leading cause of heart attacks, strokes and chronic kidney disease. Also, chronic kidney disease can cause high blood pressure. Chronic kidney disease (CKD) has no cure, but treatment can help relieve symptoms and prevent it from worsening. While the damage to your kidneys cannot be reversed, precautions to maintain them as healthy for as long as possible. The treatment will depend on the stage of CKD.

“Chronic-kidney-disease-chronic-renal-failure- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic-kidney-disease-chronic-renal-failure pipeline landscape is provided which includes the disease overview and Chronic-kidney-disease-chronic-renal-failure treatment guidelines. The assessment part of the report embraces, in depth Chronic-kidney-disease-chronic-renal-failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic-kidney-disease-chronic-renal-failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic-kidney-disease-chronic-renal-failure R&D. The therapies under development are focused on novel approaches to treat/improve Chronic-kidney-disease-chronic-renal-failure.

Chronic-kidney-disease-chronic-renal-failure Emerging Drugs Chapters


This segment of the Chronic-kidney-disease-chronic-renal-failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic-kidney-disease-chronic-renal-failure Emerging Drugs


KBP-5074: KBP Biosciences

KBP Biosciences' lead product candidate, KBP-5074, is a potentially best-in-class, next-generation, non-steroidal MRA discovered and developed by KBP's scientists, is being developed globally to initially treat Stage 3b/4, or moderate-to-severe, CKD patients with uncontrolled hypertension. KBP-5074 selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors, suggesting that KBP-5074 should be effective in blocking the hypertensive and renal tissue damaging effects of aldosterone with reduced risk of pro-diabetic and adverse endocrine effects. In clinical trials conducted to-date, it has demonstrated an ability to lower blood pressure without androgenic effects such as hirsutism, obesity and gynecomastia. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Uncontrolled Hypertension and Moderate or Severe CKD.

Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company

Empagliflozin (BI10773) is a chemical entity that inhibits the sodium glucose co-transporter-2 (SGLT 2). BI10773 is being studied in collaboration with Boehringer Ingelheim as a treatment for chronic kidney disease.

ALLN-346: Allena Pharmaceuticals

ALLN-346 is an investigational first-in-class, non-absorbed, orally administered enzyme for the treatment of hyperuricemia and gout, a metabolic disorder characterized by high systemic levels of urate that can lead to several complications, including arthritis, kidney stones, and CKD.

US-APR2020: Kibow Pharma

US-APR2020 is a natural probiotics formulation that metabolizes nitrogenous waste, which generally diffuses from the circulating bloodstream into the bowel. When these waste products accumulate in high concentrations in the blood, they become highly toxic and can cause severe damage to many organ systems if they are not properly excreted. US-APR2020 utilizes nitrogenous wastes as nutrients. As probiotics grow and multiply, they consume more nitrogenous waste and effectively maintain healthy kidney function.

MEDI8367: AstraZeneca

Medi8367 is an antibody which is used to treat Chronic Kidney Disease. It specifically binds human integrin β8 and works allosterically reducing its affinity for the LAP domain, hence preventing β8-mediated TGFβ activation but not its cell adhesion function.

Chronic-kidney-disease-chronic-renal-failure: Therapeutic Assessment


This segment of the report provides insights about the different Chronic-kidney-disease-chronic-renal-failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic-kidney-disease-chronic-renal-failure


There are approx. 50+ key companies which are developing the therapies for Chronic-kidney-disease-chronic-renal-failure. The companies which have their Chronic-kidney-disease-chronic-renal-failure drug candidates in the most advanced stage, i.e. phase III include, KBP Biosciences.

Phases


This report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Chronic-kidney-disease-chronic-renal-failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic-kidney-disease-chronic-renal-failure: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic-kidney-disease-chronic-renal-failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic-kidney-disease-chronic-renal-failure drugs.

Chronic-kidney-disease-chronic-renal-failure Report Insights

  • Chronic-kidney-disease-chronic-renal-failure Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Chronic-kidney-disease-chronic-renal-failure Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Chronic-kidney-disease-chronic-renal-failure drugs?
  • How many Chronic-kidney-disease-chronic-renal-failure drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic-kidney-disease-chronic-renal-failure?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic-kidney-disease-chronic-renal-failure therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic-kidney-disease-chronic-renal-failure and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • KBP Biosciences
  • Eli Lilly and Company
  • Novo Nordisk
  • Prokidney
  • Boryung Pharmaceutical
  • Boehringer Ingelheim
  • Cadila Healthcare Limited
  • AM-Pharma
  • DiaMedica Therapeutics
  • Allena Pharmaceuticals
  • AstraZeneca
  • Kibow Pharma
  • Bayer
  • Roche
  • Caladrius Biosciences
  • UnicoCell Biomed
  • Scohia Pharma
  • Unicycive Therapeutics
  • Senda Biosciences
  • Sarfez Pharmaceuticals
  • Rege Nephro
  • Orgenesis
  • Oisin Biotechnologies
  • Aria Pharmaceuticals
  • RedHill Biopharma
  • BERGENBIO
  • GNI Group

Key Products

  • KBP-5074
  • Ziltivekimab
  • Semaglutide
  • Fimasartan
  • Empagliflozin
  • Ilofotase alfa
  • DM199
  • ALLN-346
  • Zibotentan
  • Verinurad
  • US-APR2020
  • Runcaciguat
  • Pirfenidone
  • BI-685509
  • AZD9977
  • AZD5718
  • ELIXCYTE
  • MEDI8367
  • Cellgram-CKD
  • AZD8233
  • SCO-116


This product will be delivered within 1-3 business days.

Table of Contents

IntroductionExecutive Summary
Chronic-kidney-disease-chronic-renal-failure: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Chronic-kidney-disease-chronic-renal-failure- Analytical Perspective
Late Stage Products (Pre-Registration)
  • Comparative Analysis
Drug Name : Company Name
  • Product Description
  • Research and Development
  • Product Development Activities

Last Stage Products (Phase III)
  • Comparative Analysis

KBP-5074: KBP Biosciences
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)
  • Comparative Analysis
ALLN-346: Allena Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)
  • Comparative Analysis

MEDI8367: AstraZeneca
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Chronic-kidney-disease-chronic-renal-failure Key CompaniesChronic-kidney-disease-chronic-renal-failure Key ProductsChronic-kidney-disease-chronic-renal-failure - Unmet NeedsChronic-kidney-disease-chronic-renal-failure - Market Drivers and BarriersChronic-kidney-disease-chronic-renal-failure - Future Perspectives and ConclusionChronic-kidney-disease-chronic-renal-failure Analyst ViewsChronic-kidney-disease-chronic-renal-failure Key Companies
List of Tables
Table 1 Total Products for Chronic-kidney-disease-chronic-renal-failure
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Chronic-kidney-disease-chronic-renal-failure
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • KBP Biosciences
  • Eli Lilly and Company
  • Novo Nordisk
  • Prokidney
  • Boryung Pharmaceutical
  • Boehringer Ingelheim
  • Cadila Healthcare Limited
  • AM-Pharma
  • DiaMedica Therapeutics
  • Allena Pharmaceuticals
  • AstraZeneca
  • Kibow Pharma
  • Bayer
  • Roche
  • Caladrius Biosciences
  • UnicoCell Biomed
  • Scohia Pharma
  • Unicycive Therapeutics
  • Senda Biosciences
  • Sarfez Pharmaceuticals
  • Rege Nephro
  • Orgenesis
  • Oisin Biotechnologies
  • Aria Pharmaceuticals
  • RedHill Biopharma
  • BERGENBIO
  • GNI Group